Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News ImageneBio Inc IMA

Healthcare Biotechnology
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was... see more

Recent & Breaking News (NDAQ:IMA)

ImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program Update

GlobeNewswire 5 days ago

ImageneBio Announces $30 Million Private Placement

GlobeNewswire April 13, 2026

ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 17, 2026

ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

GlobeNewswire March 10, 2026

ImageneBio to Participate in Leerink Global Healthcare Conference

GlobeNewswire February 26, 2026

ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

GlobeNewswire February 10, 2026

ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team

GlobeNewswire November 12, 2025

ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences

GlobeNewswire November 6, 2025

ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire August 1, 2025

Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million

GlobeNewswire July 25, 2025

Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company

GlobeNewswire July 23, 2025

Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals

GlobeNewswire July 15, 2025

Ikena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote "FOR" Proposed Merger with Inmagene Biopharmaceuticals

GlobeNewswire July 11, 2025

Traws Pharma Announces Management Updates

GlobeNewswire March 28, 2025

Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement

GlobeNewswire December 23, 2024

Ikena Oncology Reports Third Quarter 2024 Financial Results

GlobeNewswire November 7, 2024

Ikena Oncology Reports Second Quarter 2024 Financial Results

GlobeNewswire August 8, 2024

UPDATE - Ikena Oncology Announces Strategic Update

GlobeNewswire May 28, 2024

Ikena Oncology Announces Strategic Update

GlobeNewswire May 28, 2024

Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update

GlobeNewswire May 13, 2024

Podcasts